Ireland approved Aurora’s cannabidiol product under its Medical Cannabis Access Program (MCAP) for the treatment of spasticity related to multiple sclerosis, chemotherapy-induced nausea and vomiting and treatment-resistant epilepsy. It is one of only two products to date to gain such authorization under the program.
Aurora’s Chief Product Officer, Dr. Shane Morris, said he expects the firm will be able to offer treatments for more medical conditions in the future.
“We look forward to more of Aurora’s high-quality medicines being approved, so that more patients can benefit from the MCAP in Ireland,” he said in a news release. “We will continue to work closely with all parties and state agencies to facilitate further availability.”
Ireland’s Minister for Health, Simon Harris, signed MCAP into law in June. It aims to facilitate access to cannabis-based medical products and is scheduled to run for 5 years